

# Association of Patients' Geographic Origins with Viral Hepatitis Co-infection Patterns, Spain

**Santiago Pérez Cachafeiro, Ana María Caro-Murillo, Juan Berenguer, Ferran Segura, Felix Gutiérrez, Francesc Vidal, María Ángeles Martínez-Pérez, Julio Sola, Roberto Muga, Santiago Moreno, and Julia Del Amo, on behalf of Cohort of the Spanish Aids Research Network<sup>1</sup>**

To determine if hepatitis C virus seropositivity and active hepatitis B virus infection in HIV-positive patients vary with patients' geographic origins, we studied co-infections in HIV-seropositive adults. Active hepatitis B infection was more prevalent in persons from Africa, and hepatitis C seropositivity was more common in persons from eastern Europe.

Since the introduction of highly active antiretroviral treatment (HAART), non-AIDS defining conditions have become major causes of illness and death in HIV-infected patients. In particular, liver disease has emerged as a major cause of death in the HAART era (1,2). In HIV-infected patients, chronic liver conditions are mostly caused by hepatitis C virus (HCV) and hepatitis B virus (HBV) (3,4).

Worldwide distribution of both viruses is heterogeneous because of different patterns of transmission (5,6). In

Author affiliations: Fundación IDI Complejo Hospitalario de Pontevedra, Pontevedra, Spain (S. Pérez Cachafeiro); National Centre of Epidemiology Instituto de Salud Carlos III, Madrid, Spain (A.M. Caro-Murillo, J. Del Amo); Hospital General Universitario Gregorio Marañón, Madrid (J. Berenguer); Corporació Sanitària Parc Taulí, Sabadell, Spain (F. Segura); Hospital Universitario de Elche, Elche, Spain (F. Gutiérrez); Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain (F. Vidal), Hospital Universitario San Cecilio, Granada, Spain (M.Á. Martínez-Pérez), Hospital de Navarra, Pamplona, Spain (J. Sola); Hospital Universitari Germans Trias i Pujol, Badalona, Spain (R. Muga); and Hospital Universitario Ramon y Cajal, Madrid (S. Moreno)

DOI: 10.3201/eid1706.091810

addition, HBV immunization programs at birth were implemented in some countries during the 1990s, which has led to a decrease in the proportion of chronic HBV carriers (6). As a consequence of these different patterns of risk and immunization, HCV and HBV prevalence vary across countries and even across regions in the same country (7,8). Several studies have addressed HBV and HCV prevalence in migrants and ethnic minorities (9,10), but few studied viral hepatitis co-infections in HIV-infected persons according to the patients' geographic origins (11,12).

In Spain, as in other high-income countries, migrants from developing countries represent a growing proportion of persons with HIV-infections (13). The question we addressed in our study was whether HCV seropositivity and active HBV infection in HIV-positive patients vary with the patients' geographic origins.

## The Study

To assess this question, we defined active HBV infection as the presence in serum of hepatitis B surface antigen (HBsAg) and defined HCV seropositivity as the presence of HCV antibodies. Then we described the prevalence of HCV seropositivity and active HBV infection in HIV-positive patients from the Cohort of the Spanish AIDS Research Network (CoRIS) who had never received HAART, according to their geographic origin. In addition, we explored the association between HCV seropositivity and active HBV infection with geographic origin, taking into account potential confounders.

CoRIS is an open, prospective cohort, which integrates data from 31 centers from 13 of the 17 autonomous communities in Spain. CoRIS inclusion criteria for patients are the following: >13 years of age, new to the center, and previously untreated with HAART. A detailed description of this cohort has been previously reported (14). Patients signed informed consent and the study was approved by the ethics committees at each participant hospital. For the purpose of this study, we collected data from all 4,419 HIV-positive HAART-naïve patients included in CoRIS from January 1, 2004, through November 30, 2008.

Serologic tests for HBV and HCV were done by the clinical laboratories associated with each of the participating sites by using commercially available ELISAs to detect HBsAg. HCV antibody testing was performed with a commercial ELISA, and positive results were confirmed by immunoblot. For the HBV analyses, we considered only those patients who had positive HBsAg results at study entry (n = 3,824). Similarly, for the HCV analyses, we only considered patients with positive HCV antibody test results at entry (n = 3,867).

<sup>1</sup>A complete listing of the members of the Spanish AIDS Research Network is provided in the online Technical Appendix ([www.cdc.gov/EID/content/17/6/1116-Techapp.pdf](http://www.cdc.gov/EID/content/17/6/1116-Techapp.pdf))

CoRIS collected the following variables at cohort entry: gender (male or female), age (<31, 31–40, or >40 years), transmission category (injection drug users [IDU], men who have sex with men [MSM], heterosexual contact, and other/unknown), educational level (no studies, primary school, secondary school, university, and unknown), geographic origin (Spain, non-Spanish western Europe, eastern Europe and Russia, sub-Saharan Africa, North Africa, Latin America, and other/unknown origin), serologic markers (positive, negative, and unknown).

Description of baseline characteristics was done by frequency distributions. A  $\chi^2$  test was used to compare proportions between geographic origins. We calculated univariate odds ratios of association of co-infection with sex, transmission category, age at entry into cohort, educational level, and geographic origin. Trend score tests were used with age and educational level. Multivariate logistic regression analysis was used to estimate the association of geographic origin with HCV and active HBV co-infections. Taking into account previous studies (7–11), we decided to include the following variables in the multivariate analyses: gender, transmission category, age at entry to cohort, and educational level. We used likelihood ratio tests to address the adequacy of the model.

Differences at baseline according to geographic origin are shown in Table 1. In all studied populations, prevalence of HCV seropositivity was 21.8% (95% confidence interval [CI] 20.5%–23.1%). Compared with Spaniards, for whom prevalence was 26.5%, HCV seropositivity was higher in migrants from eastern Europe, 45.9% ( $p < 0.01$ ), and lower in persons from sub-Saharan Africa, North Africa, and

Latin America, for whom numbers were 10.1% ( $p < 0.01$ ), 16.4% ( $p = 0.09$ ), and 4.9% ( $p < 0.01$ ), respectively. No significant differences were observed when seropositivity was compared with that of persons from Western Europe, 22.3% ( $p = 0.30$ ).

In all studied populations, active HBV infection was 5.8% (95% CI 5.1%–6.6%); when compared to prevalence of infections in persons born in Spain (4.9%), active HBV infection was more common in persons from western Europe, sub-Saharan Africa, and North Africa with 11.2% ( $p < 0.01$ ), 11.1% ( $p < 0.01$ ), and 10.9% ( $p < 0.05$ ), respectively. No significant differences were observed between prevalence in Spain and prevalence in persons from eastern Europe and Russia, 8.4% ( $p = 0.15$ ) and Latin America, 5.6% ( $p = 0.46$ ).

Marked differences in HCV seropositivity and active HBV infection prevalence according to transmission category were also observed, showing higher prevalence of co-infection in IDU (HCV 89.5%; HBV 7.8%) than in heterosexual persons (HCV 13.0%,  $p < 0.01$ ; HBV 5.1%,  $p < 0.05$ ) or MSM (HCV 3.5%,  $p < 0.01$ ; HBV 5.8%,  $p = 0.09$ ). Active HBV infection was more common in MSM (8.2%) than in heterosexual persons (2.8%,  $p < 0.01$ ) only in HIV-positive patients from Latin America.

In analyses adjusted for age group (<31, 31–40, or >40 years), gender, transmission category (heterosexual, IDU, MSM, other) and level of education (no studies, primary school, secondary school, university, unknown), geographic origin remains a strong risk factor for HCV seropositivity (Table 2). Geographic origin in eastern Europe and Russia was significantly associated with higher prevalence of HCV

Table 1. Sociodemographic characteristics of patients in Cohort of the Spanish Aids Research Network by geographic origin, Spain, 2004–2008\*

Patient characteristic	No. (%) patients							
	All	Spain	Western Europe	Eastern Europe	Sub-Saharan Africa	North Africa	Latin America	Other/UNK
Total	4,419	3,023	136	90	315	67	740	48
Female sex	1,003 (22.70)	574 (18.99)	15 (11.03)†	41 (45.56)‡	182 (57.78)‡	24 (35.82)‡	166 (22.43)†	1 (2.08)
Age, y								
<31	1,344 (30.42)	751 (24.84)	23 (16.91)	56 (62.22)‡	147 (46.67)‡	18 (26.87)	330 (44.59)‡	19 (39.58)
31–40	1,750 (39.61)	1,197 (39.60)	76 (55.88)‡	23 (25.56)	105 (33.33)	32 (47.76)	301 (40.68)	16 (33.33)
>40	1,325 (29.98)	1,075 (35.56)	37 (27.21)	11 (12.22)	63 (20.00)†	17 (25.37)	109 (14.73)‡	13 (27.08)
Transmission								
Heterosexual	1,666 (37.70)	960 (31.76)	30 (22.06)	48 (53.33)‡	284 (90.16)‡	50 (74.63)‡	282 (38.11)†	12 (25.00)
IDU	721 (16.32)	641 (21.20)	25 (18.38)	24 (26.67)	5 (1.59)	6 (8.96)	14 (1.89)	6 (12.50)
MSM	1,852 (41.91)	1,301 (43.04)	78 (57.35)†	12 (13.33)†	2 (0.63)	6 (8.96)	427 (57.70)‡	26 (54.17)
Other/UNK	180 (4.07)	121 (4.00)	3 (2.21)	6 (6.67)	24 (7.62)	5 (7.46)	17 (2.30)	4 (8.33)
Level of studies								
No studies	303 (6.86)	152 (5.03)	5 (3.68)	9 (10.00)	78 (24.76)‡	15 (22.39)‡	41 (5.54)	3 (6.25)
Primary	1,416 (32.04)	998 (33.01)	30 (22.06)	33 (36.67)	92 (29.21)	19 (28.36)	236 (31.89)	8 (16.67)
Secondary	1,203 (27.22)	839 (27.75)	42 (30.88)	28 (31.11)	39 (12.38)†	14 (20.90)	231 (31.22)	10 (20.83)
University	642 (14.53)	459 (15.18)	39 (28.68)†	7 (7.78)	10 (3.17)	7 (10.45)	113 (15.27)	7 (14.58)
Unknown	855 (19.35)	575 (19.02)	20 (14.71)	13 (14.44)	96 (30.48)†	12 (17.91)	119 (16.08)	20 (41.67)†

\*IDU, injection drug user; MSM, men who have sex with men; UNK, unknown.

† $p < 0.05$ ,  $\chi^2$  test for the difference between proportions of persons from each place of origin and persons born in Spain.

‡ $p < 0.01$ .

Table 2. Frequencies of hepatitis C virus seropositivity and/or active hepatitis B virus-HIV coinfection in HIV-infected patients and multivariate odds ratio of association to sociodemographic variables, Spain, 2004–2008\*

Variable	HCV seropositivity		HBsAg seropositivity	
	No. (%) patients	Adjusted OR (95% CI)	No. (%) patients	Adjusted OR (95% CI)
Sex				
M	3,012 (21.18)	NA	2,952 (6.47)	1.00
F	855 (24.09)		872 (3.67)	0.44 (0.28–0.68)
Age, y				
<31	1,168 (9.76)	1.00	1,119 (5.36)	NA
31–40	1,532 (24.22)	2.60 (1.84–3.67)	1,515 (5.54)	
>40	1,166 (30.79)	3.85 (2.72–5.46)	1,189 (6.64)	
Transmission category				
Heterosexual	1,400 (13)	1.00	1,467 (5.11)	1.00
Injection drug use	639 (89.51)	50.67 (36.85–69.68)	618 (7.77)	1.71 (1.11–2.63)
Men who have sex with men	1,670 (3.53)	0.33 (0.24–0.45)	1,584 (5.81)	1.33 (0.89–1.98)
Other/unknown	158 (19.62)	1.50 (0.97–2.33)	155 (5.16)	0.97 (0.45–2.09)
Level of studies				
No studies	272 (32.72)	1.00	262 (8.78)	1.00
Primary school	1,286 (31.18)	0.80 (0.52–1.24)	1,244 (6.75)	0.82 (0.5–1.36)
Secondary school	1,108 (13.09)	0.51 (0.32–0.82)	1,054 (4.27)	0.48 (0.27–0.84)
University	591 (5.75)	0.42 (0.24–0.76)	560 (5.54)	0.61 (0.33–1.12)
Unknown	610 (28.69)	1.05 (0.66–1.67)	704 (5.68)	0.64 (0.37–1.11)
Geographic origin				
Spain	2,650 (26.53)	1.00	2,628 (4.91)	1.00
Western Europe	121 (22.31)	1.01 (0.51–2.03)	116 (11.21)	2.38 (1.29–4.39)
Eastern Europe	85 (45.88)	3.76 (2.06–6.83)	83 (8.43)	2.15 (0.96–4.84)
Sub-Saharan Africa	268 (10.07)	0.60 (0.38–0.96)	280 (11.07)	3.63 (2.22–5.92)
North Africa	55 (16.36)	0.51 (0.2–1.34)	55 (10.91)	2.96 (1.21–7.23)
Latin America	648 (4.94)	0.45 (0.29–0.69)	622 (5.63)	1.30 (0.87–1.93)
Other/unknown	40 (17.5)	0.81 (0.26–2.5)	40 (5.00)	0.98 (0.23–4.15)

\*Variables included in the multivariate analyses: gender, transmission category, age at entry into cohort, and educational level. HCV, hepatitis C virus; HBsAg, hepatitis B virus surface antigen; OR, odds ratio; CI, confidence interval; NA, not associated in the model.

seropositivity than was origin in Spain, and sub-Saharan African, North African, and Latin American origins were associated with lower prevalence of HCV seropositivity. Nonetheless, IDU transmission category was the factor that showed the greatest association with HCV seropositivity. Analyses of association of geographic origin to active HBV infection, with data adjusted for age, gender, transmission category, and level of education (Table 2), showed that origin in Western Europe, sub-Saharan Africa, and North Africa was associated with a significantly higher prevalence of active HBV infection than origin in Spain.

CoRIS annually undertakes both internal and external quality audits. The cohort represents the HIV-positive population that initiates care at hospitals in Spain, i.e., those whose conditions have been newly diagnosed and, therefore, they have not begun HAART at the time of entry at cohort. Geographic origin and transmission categories are collected as reported by the patient, which could produce some misclassification. However, our results are consistent, and the association of both co-infections with geographic origin is unlikely to be biased. We could not hypothesize about risks at origin since data on exposure in country of origin (e.g., vaccination, occupation, health care received) are not collected in our database.

## Conclusions

Geographic origin of HIV-positive patients influences the epidemiology of both HCV seropositivity and active HBV infection in HIV-positive patients who begin HIV clinical care in Spain. Although injection drug use remains the main risk factor for HCV seropositivity as reported by other studies (15), differences by geographic origin are maintained in multivariate analyses. For active HBV infection, geographic origin is the major risk factor shown by HIV-positive patients who seek clinical care for HIV in Spain. Our findings suggest that the background prevalence of HCV and HBV co-infections in different migrant communities does play a role in shaping the epidemiology of both co-infections in HIV-positive patients.

This research was supported by a grant from the Spanish National Institute of Health (ISCIII RD06/006).


Dr Pérez Cachafeiro earned a master of science degree in Control of Infectious Diseases from the London School of Hygiene and Tropical Medicine. He is completing his PhD in the field of HIV and viral hepatitis co-infections while working as a family physician and epidemiologist at Pontevedra Hospital Complex.

## References

1. Mocroft A, Soriano V, Rockstroh J, Reiss P, Kirk O, de Wit S, et al. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? *AIDS*. 2005;19:2117–25. doi:10.1097/01.aids.0000194799.43799.ea
2. Lumbreras B, Jarrín I, del Amo J, Pérez-Hoyos S, Muga R, García-de la Hera M, et al. Impact of hepatitis C infection on long-term mortality of injecting drug users from 1990 to 2002: differences before and after HAART. *AIDS*. 2006;20:111–6. doi:10.1097/01.aids.0000196164.71388.3b
3. Puoti M, Spinetti A, Ghezzi A, Donato F, Zaltron S, Putzolu V, et al. Mortality for liver disease in patients with HIV infection: a cohort study. *J Acquir Immune Defic Syndr*. 2000;24:211–7.
4. Salmon-Ceron D, Lewden C, Morlat P, Bévillacqua S, Jougle A, Bonnet F, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. *J Hepatol*. 2005;42:799–805. doi:10.1016/j.jhep.2005.01.022
5. World Health Organization. Hepatitis C [cited 2009 Jan 25]. [http://www.who.int/immunization/topics/hepatitis\\_c/en/index.html](http://www.who.int/immunization/topics/hepatitis_c/en/index.html).
6. World Health Organization. Hepatitis B [cited 2009 Jan 25]. [http://www.who.int/immunization\\_delivery/new\\_vaccines/hepb/en/index.html](http://www.who.int/immunization_delivery/new_vaccines/hepb/en/index.html).
7. Backus LI, Boothroyd D, Deyton LR. HIV, hepatitis C and HIV/hepatitis C virus co-infection in vulnerable populations. *AIDS*. 2005;19(Suppl 3):S13–9. doi:10.1097/01.aids.0000192065.09281.01
8. Touzet S, Kraemer L, Colin C, Pradat P, Lanoir D, Bailly F, et al. Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group (Hepatitis C European Network for Co-operative Research). *Eur J Gastroenterol Hepatol*. 2000;12:667–78. doi:10.1097/00042737-200012060-00017
9. Veldhuijzen IK, van Driel HF, Vos D, de Zwart O, van Doornum GJ, de Man RA, et al. Viral hepatitis in a multi-ethnic neighborhood in the Netherlands: results of a community-based study in a low prevalence country. *Int J Infect Dis*. 2009;13:e9–13. doi:10.1016/j.ijid.2008.05.1224
10. Majori S, Baldo V, Tommasi I, Malizia M, Floreani A, Monteiro G, et al. Hepatitis A, B, and C infection in a community of sub-Saharan immigrants living in Verona (Italy). *J Travel Med*. 2008;15:323–7. doi:10.1111/j.1708-8305.2008.00230.x
11. Larsen C, Pialoux G, Salmon D, Antona D, Le Strata Y, Piroth L, et al. Prevalence of hepatitis C and hepatitis B infection in the HIV-infected population of France, 2004. *Euro Surveill*. 2008;13:pii:8888.
12. Uddin G, Shoeb D, Solaiman S, Marley R, Gore C, Ramsay M, et al. Prevalence of chronic viral hepatitis in people of south Asian ethnicity living in England: the prevalence cannot necessarily be predicted from the prevalence in the country of origin. *J Viral Hepat*. 2010;17:327–35. doi:10.1111/j.1365-2893.2009.01240.x
13. Caro-Murillo AM, Gutierrez F, Manuel Ramos J, Sobrino P, Miro JM, Lopez-Cortes LF, et al. HIV infection in immigrants in Spain: epidemiological characteristics and clinical presentation in the CoRIS Cohort (2004–2006) [in Spanish]. *Enferm Infecc Microbiol Clin*. 2009;27:380–8. doi:10.1016/j.eimc.2008.10.007
14. Caro-Murillo AM, Castilla J, Pérez-Hoyos S, Miró JM, Podzamczar D, Rubio R, et al. Spanish cohort of naïve HIV-infected patients (CoRIS): rationale, organization and initial results [in Spanish]. *Enferm Infecc Microbiol Clin*. 2007;25:23–31. doi:10.1157/13096749
15. Pérez Cachafeiro S, Del Amo J, Iribarren JA, Salavert Leiti M, Gutiérrez F, Moreno A, et al. Decrease in serial prevalence of coinfection with hepatitis C virus among HIV-infected patients in Spain, 1997–2006. *Clin Infect Dis*. 2009;48:1467–70. doi:10.1086/598333

Address for correspondence: Santiago Pérez Cachafeiro, Metodólogo Fundación IDI-CHOP, Complejo Hospitalario de Pontevedra, Hospital Montecelo Planta (-1), Mourente s/n, 36164 Pontevedra, Spain; email: [santiago.perez.cachafeiro@sergas.es](mailto:santiago.perez.cachafeiro@sergas.es)

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the Centers for Disease Control and Prevention or the institutions with which the authors are affiliated.



## GovDelivery

Manage your email alerts so you only receive content of interest to you.

Sign up for an Online Subscription:

[www.cdc.gov/ncidod/eid/subscribe.htm](http://www.cdc.gov/ncidod/eid/subscribe.htm)